Your search for non small cell lung cancer returned 17 results

Active Filters

Click on a filter below to refine your search. Remove a filter to broaden your search.

Mpr-drug-news remove
Lea Eslava-Kim, PharmD remove
Drugs in the Pipeline remove

Your search for non small cell lung cancer returned 17 results

Sort Results:

Relevant Recent
Drugs in the Pipeline

Opdivo Granted Priority Review for Advanced Renal Cancer

The FDA has accepted for filing and granted priority review to the supplemental Biologics License Application (sBLA) for Opdivo (nivolumab; BMS) for the treatment of patients with advanced renal cell carcinoma (RCC) who have received prior anti-angiogenic therapy.
Drugs in the Pipeline

Positive Phase 3 Results for Opdivo in Renal Cell Carcinoma

Bristol-Myers Squibb announced positive results from CheckMate -025, a Phase 3 study comparing Opdivo (nivolumab) to everolimus in advanced renal cell carcinoma (RCC) after prior anti-angiogenic treatment.
Drugs in the Pipeline

FDA Designates Avelumab Orphan Drug for Skin Cancer

The FDA has granted Orphan Drug designation to the investigational cancer immunotherapy avelumab (Pfizer/Merck) for the treatment of Merkel cell carcinoma (MCC).
Drugs in the Pipeline

FDA to Review Ready-to-Dilute Pemetrexed Formulation

The FDA has accepted for review the New Drug Application (NDA) for Eagle's ready-to-dilute (RTD) Pemetrexed Injection 25mg/mL for the treatment of locally advanced or metastatic nonsquamous non-small cell lung cancer and mesothelioma (in combination with cisplatin).
Drugs in the Pipeline

Initial NDA for Investigational ALK Inhibitor Submitted to FDA

Ariad Pharmaceuticals announced the initiation of the first part of a rolling New Drug Application (NDA) submission to the Food and Drug Administration (FDA) for its investigational agent, brigatinib, for the treatment of patients with anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC) who are resistant to crizotinib.
Drugs in the Pipeline

Study on Opdivo for Head, Neck CA Halted Early

Bristol-Myers Squibb announced that the CheckMate -141 trial evaluating Opdivo (nivolumab) vs. investigator's choice in patients with recurrent or metastatic platinum-refractory squamous cell carcinoma of the head and neck (SCCHN) was stopped early due to the study meeting its primary endpoint.